Matinas BioPharma Holdings, Inc.

Equities

MTNB

US5768101058

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:45:40 23/05/2024 pm IST			5-day change	1st Jan Change
0.168 ^USD	+0.18%		-3.24%	-22.57%

09/05	Transcript : Matinas BioPharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Matinas Biopharma Holdings, Inc. Announces Termination of Dominick M. Dipaolo as Its Senior Vice President of Quality and Regulatory Compliance

June 19, 2018 at 02:54 am IST

On June 14, 2018, Matinas BioPharma Holdings, Inc. terminated the employment of Dominick M. DiPaolo who served as the Company’s Senior Vice President of Quality and Regulatory Compliance effective immediately.

Latest news about Matinas BioPharma Holdings, Inc.

Transcript : Matinas BioPharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024	10/05
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
In Vivo Efficacy of Matinas BioPharma?s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy	30/04	CI
Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024	28/03
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation	25/03	CI
North American Morning Briefing : Markets on Hold -2-	20/03	DJ
North American Morning Briefing : Stock Futures -2-	13/03	DJ
Matinas Biopharma Provides Positive Outcomes Update on the Mat2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution	26/02	CI
Matinas Reaches Agreement With FDA For Late-Stage Invasive Aspergillosis Trial	21/02	MT
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis	20/02	CI
Sector Update: Health Care Stocks Gain Late Afternoon	28/12	MT
Matinas BioPharma Shares Rise After Studies Show Successful Oral Delivery of Genetic Material Using its Technology	27/12	MT
Sector Update: Health Care	28/12	MT
Matinas BioPharma Holdings, Inc. Demonstrates in Vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides	27/12	CI
Matinas Biopharma Holdings, Inc. Provides Update to Mat2203 Regulatory and Development Pathway Following Feedback from FDA	21/12	CI
Transcript : Matinas BioPharma Holdings, Inc., Q3 2023 Earnings Call, Nov 08, 2023	09/11
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Matinas Biopharma Holdings, Inc. Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model	07/11	CI
US Equity Markets Close Higher Wednesday Despite Stronger-Than-Expected Wholesale Prices	12/23/12	MT
Top Midday Gainers	11/23/11	MT
Matinas BioPharma Holdings, Inc. Announces Complete Clinical Resolution of a Patient?s Recurrent Hemorrhagic Cystitis Due to Candida krusei Following Treatment with MAT2203	11/23/11	CI
Matinas BioPharma Holdings, Inc.(NYSEAM:MTNB) dropped from S&P Global BMI Index	18/23/18	CI
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of Mat2203 in the IDSA Journal Clinical Infectious Diseases	22/23/22	CI
Transcript : Matinas BioPharma Holdings, Inc., Q2 2023 Earnings Call, Aug 09, 2023	10/23/10

Chart Matinas BioPharma Holdings, Inc.

Duration

Period

More charts

Company Profile

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFÎ±.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1677 USD

Average target price

0.8667 USD

Spread / Average Target

+416.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MATINAS BIOPHARMA HOLDINGS, INC.	-22.57%	42.06M
VERTEX PHARMACEUTICALS INCORPORATED	+10.88%	115B
REGENERON PHARMACEUTICALS, INC.	+12.45%	106B
BIONTECH SE	-4.30%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.51%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.21%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.63%	12.13B

Bio Therapeutic Drugs